Platelet dysfunction in hypercholesterolemia mice, two Alzheimer’s disease mouse models and in human patients with Alzheimer’s disease

Biogerontology

Volumn 16, Issue 4, 2015, Pages 543-558

  Plagg, Barbara ^a   Marksteiner, Josef ^b   Kniewallner, Kathrin M ^a   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Landeskrankenhaus Hall ^*  (Austria)

Author keywords

Alzheimer s disease; Amyloid precursor protein; Biomarker; Epidermal growth factor; Platelets; Serotonin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; EPIDERMAL GROWTH FACTOR; PADGEM PROTEIN; SEROTONIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; THROMBOCYTE; THROMBOCYTE DYSFUNCTION; VERY ELDERLY; ANIMAL; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE MODEL; GENETICS; GENOTYPE; HYPERLIPIDEMIA; METABOLISM; PATHOLOGY; PHENOTYPE; SPECIES DIFFERENCE; TIME FACTOR; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; BIOMARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; FEMALE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; MALE; MICE, TRANSGENIC; PHENOTYPE; SEROTONIN; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84933672371     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-015-9580-1     Document Type: Article

References (79)

1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27(12):1029–1034
2. Andersson A, Adolfsson R, Eriksson K, Marcusson J (1991) Platelet [3H]paroxetine binding to 5-HT uptake sites in Alzheimer’s disease. Neurobiol Aging 12(5):531–534
3. Arora RC, Emery OB, Meltzer HY (1991) Serotonin uptake in the blood platelets of Alzheimer’s disease patients. Neurology 41(8):1307–1309
4. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer’s disease. Curr Med Chem 14(27):2848–2864
5. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM (2000) Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54(10):1907–1909
6. Björkqvist M, Ohlsson M, Minthon L, Hansson O (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One 7(1):e29868
7. Blennow K (2005) CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5(5):661–672
8. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131–144
9. Borroni B, Colciaghi F, Archetti S, Marcello E, Caimi L, Di Luca M, Padovani A (2004) Predicting cognitive decline in Alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Dis 18(1):32–34
10. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A (2010) Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 45(1):53–56
11. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Alzheimer Disease Neuroimaging Initiative, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16(7):848–850
12. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P et al (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem 265(26):15977–15983
13. Casoli T, Di Stefano G, Balietti M, Solazzi M, Giorgetti B, Fattoretti P (2010) Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets. Biogerontology 11(5):627–633
14. Chasseigneaux S, Dinc L, Rose C, Chabret C, Coulpier F, Topilko P, Mauger G, Allinquant B (2011) Secreted amyloid precursor protein β and secreted amyloid precursor protein α induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One 6(1):e16301
15. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophy Res Commun 213(1):96–103
16. Chiu MJ, Yang SY, Horng HE, Yang CC, Chen TF, Chieh JJ, Chen HH, Chen TC, Ho CS, Chang SF, Liu HC, Hong CY, Yang HC (2013) Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 4(12):1530–1536
17. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, Padovani A, Di Luca M (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62(3):498–501
18. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279(19):20296–20306
19. Di Luca M, Pastorino L, Cattabeni F, Zanardi R, Scarone S, Racagni G, Smeraldi E, Perez J (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and down syndrome. Arch Neurol 53(11):1162–1166
20. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, Trabucchi M, Cattabeni F, Padovani A (1998) Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55(9):1195–1200
21. Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F (2000) Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol 405(1–3):277–283
22. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746
23. Ehrlich D, Hochstrasser T, Humpel C (2013) Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets. Platelets 24(1):26–36
24. El Haouari M, Rosado JA (2009) Platelet function in hypertension. Blood Cells Mol Dis 42(1):38–40
25. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res 74(3):386–392
26. Gardella JE, Ghiso J, Gorgone GA, Marratta D, Kaplan AP, Frangione B, Gorevic PD (1990) Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem Biophys Res Commun 173(3):1292–1298
27. Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Investig 115(12):3378–3384
28. Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG (1990) Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer’s disease using PCR. Neuron 4:253–267
29. Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, Jucker M, Elvers M (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One 9(2):e90523
30. Hochstrasser T, Marksteiner J, Humpel C (2012a) Telomere length is age-dependent and reduced in monocytes of Alzheimer patients. Exp Gerontol 47(2):160–163
31. Hochstrasser T, Ehrlich D, Marksteiner J, Sperner-Unterweger B, Humpel C (2012b) Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients. Curr Alzheimer Res 9(8):982–989
32. Hohsfield LA, Ehrlich D, Humpel C (2014) Intravenous infusion of nerve growth factor-secreting monocytes supports the survival of cholinergic neurons in the nucleus basalis of Meynert in hypercholesterolemia brown-Norway rats. J Neurosci Res 92(3):298–306
33. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H (2012) Alzheimer’s disease neuroimaging initiative. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79(9):897–905
34. Hu N, Tan MS, Sun L, Jiang T, Wang YL, Tan L, Zhang W, Yu JT, Tan L (2014) Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer’s disease patients. Neurosci Lett 563:51–54
35. Humpel C (2011) Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol 29(1):26–32
36. 14C]5-hydroxytryptamine. Neurosci Lett 163(1):8–10
37. Järemo P, Milovanovic M, Buller C, Nilsson S, Winblad B (2013) P-selectin paradox and dementia of the Alzheimer type: circulating P-selectin is increased but platelet-bound P-selectin after agonist provocation is compromised. Scand J Clin Lab Investig 73(2):170–174
38. Jarre A, Gowert NS, Donner L, Münzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M (2014) Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal 26(9):2040–2050
39. Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schröder J, Kinscherf R (2008) Novel systemic markers for patients with Alzheimer disease?—A pilot study. Curr Alzheimer Res 5(4):358–366
40. Kokjohn TA, Van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castaño EM, Roher AE (2011) Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 1812(11):1508–1514
41. Koren P, Diver-Haber A, Adunsky A, Rabinowitz M, Hershkowitz M (1993) Uptake of serotonin into platelets of senile dementia of the Alzheimer type patients. J Gerontol 48(3):B93–B96
42. Kumar AM, Sevush S, Kumar M, Ruiz J, Eisdorfer C (1995) Peripheral serotonin in Alzheimer’s disease. Neuropsychobiology 32(1):9–12
43. Li QX, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, Beyreuther K, Masters CL (1994) Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer’s disease in human platelet and brain: surface expression on the activated human platelet. Blood 84(1):133–142
44. Li QX, Fuller SJ, Beyreuther K, Masters CL (1999) The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol 66(4):567–574
45. Marksteiner J, Humpel C (2013) Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res 10(4):297–303
46. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterhölzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 32(3):539–540
47. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944
48. Meyerson LR, Strano R, Ocheret D (1989) Diurnal concordance of human platelet serotonin content and plasma alpha-1-acid glycoprotein concentration. Pharmacol Biochem Behav 32(4):1043–1047
49. Milovanovic M, Eriksson K, Winblad B, Nilsson S, Lindahl TL, Post C, Järemo P (2014) Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clin Biochem 47(15):51–53
50. Mimica N, Mück-Seler D, Pivac N, Mustapić M, Dezeljin M, Stipcević T, Presecki P, Radonić E, Folnegović-Smalc V (2008) Platelet serotonin and monoamine oxidase in Alzheimer’s disease with psychotic features. Coll Antropol 32(Suppl 1):119–122
51. Mönning U, König G, Banati RB, Mechler H, Czech C, Gehrmann J, Schreiter-Gasser U, Masters CL, Beyreuther K (1992) Alzheimer beta A4-amyloid protein precursor in immunocompetent cells. J Biol Chem 267:23950–23956
52. Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, Babic A, Nedic G, Folnegovic-Smalc V (2009) Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 33(7):1226–1231
53. Naert G, Rivest S (2013) A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease. J Mol Cell Biol 5(5):284–293
54. Neumann K, Farías G, Slachevsky A, Perez P, Maccioni RB (2011) Human platelets tau: a potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis 25(1):103–109
55. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3):409–421
56. Ogawa T, Sugidachi A, Asai F, Koike H (2000) Reduced platelet serotonin content in rabbits with dietary hypercholesterolemia. Blood Coagul Fibrinolysis 11(4):313–319
57. Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettenati C, Mussi M, Parrinello G, Cottini E, Lenzi GL, Trabucchi M, Cattabeni F, Di Luca M (2001) Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 57(12):2243–2248
58. Patzelt J, Langer HF (2012) Platelets in angiogenesis. Curr Vasc Pharmacol 10(5):570–577
59. Prokšelj T, Jerin A, Muck-Seler D, Kogoj A (2014) Decreased platelet serotonin concentration in Alzheimer’s disease with involuntary emotional expression disorder. Neurosci Lett 578:71–74
60. Rainesalo S, Keränen T, Saransaari P, Honkaniemi J (2005) GABA and glutamate transporters are expressed in human platelets. Mol Brain Res 141(2):161–165
61. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13(11):1359–1362
62. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 5(1):18–29
63. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullum CM, Weiner MF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54(2):139–144
64. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS (1998) Platelet activation in Alzheimer disease. Arch Neurol 55(4):530–536
65. Shad KF, Aghazadeh Y, Ahmad S, Kress B (2013) Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse 67(8):541–543
66. Skovronsky DM, Lee VM, Praticò D (2001) Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 276(20):17036–17043
67. Smith CC, Betteridge DJ (1997) Reduced platelet serotonin content and release in familial hypercholesterolaemia. Atherosclerosis 130(1–2):87–92
68. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease. Brain Res Rev 61(2):69–80
69. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126(1):88–94
70. Srisawat C, Junnu S, Peerapittayamongkol C, Futrakul A, Soi-ampornkul R, Senanarong V, Praditsuwan R, Assantachai P, Neungton N (2013) The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer’s disease in Thai patients. J Clin Neurosci 20(5):644–648
71. Stellos K, Panagiota V, Kögel A, Leyhe T, Gawaz M, Laske C (2010) Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab 30(11):1817–1820
72. Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 240(1–2):53–58
73. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331(6156):528–530
74. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389
75. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev 37(8):1363–1379
76. Tukiainen E, Wikström J, Kilpeläinen H (1981) Uptake of 5-hydroxytryptamine by blood platelets in Huntington’s chorea and Alzheimer type of presenile dementia. Med Biol 59(2):116–120
77. Ullrich C, Pirchl M, Humpel C (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45(4):408–417
78. Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV (2012) Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm 119(7):815–819
79. Zetterberg H, Blennow K, Hanse E (2010) Amyloid beta and APP as biomarkers for Alzheimer’s disease. Exp Gerontol 45(1):23–29